A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer - Episode 6
Cathy Eng, MD, FACP, FASCO: There is a drug specific to NTRK fusion resistance to larotrectinib and also specifically for the NTRK inhibitors, and that is NTRK1 G595R. There is a drug specific to that called LOXO-195, which is approved to be utilized in that setting.
I would say that basically this literature regarding the NTRK fusion and its significance is important across all malignancies. Although I focus specifically on colorectal carcinoma, the NTRK fusion is more common in other malignancies, such as papillary thyroid carcinoma, salivary gland carcinoma, and more common in pediatric tumors.
It is advantageous for other malignancies, not necessarily colorectal carcinoma, but it appears to have a role, specifically even higher in the MSI [microsatellite instability]-high positive colorectal cancer tumors. And the fact that it's an oral agent with such significant response.
Once again, if the patient tolerates it well and given that there are several patients who we treat, on a day-to-day basis, with refractory colorectal carcinoma that are surgically unresectable, if they're NTRK positive, obviously this is another drug that would be advantageous in the armamentarium to treat our metastatic colorectal cancer patients.
Transcript edited for clarity.
Case: A 68-Year-Old Woman With Metastatic NTRK Fusion-Positive Colon Cancer